Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...

Astellas has invested heavily in novel technologies that are not necessarily the most successful or popular in the industry.

Marci English, head of biopharma and ophthalmology development at Astellas Pharma, said the FDA's change of heart will ...

Chief Scientific Officer Yoshitsugu Shitaka, Ph.D., won’t be so lucky. Astellas intends to create the new role of chief ...

Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (OTC:ALPMF) (OTC:ALPMY) released additional follow-up results from the Phase ...

Pfizer (PFE) and Astellas Pharma announced additional follow-up results from the Phase 3 EV-302 clinical trial evaluating the efficacy and ...

US FDA approves expanded label for Astellas’ Izervay for the treatment of geographic atrophy: Tokyo Friday, February 14, 2025, 09:00 Hrs [IST] Astellas Pharma Inc., a global lif ...

The updated label allows physicians to prescribe Izervay without a limitation on duration for patients with geographic ...

Minds + Assembly, a 2024 MM+M Agency 100 honoree, added Chuck Hemann as chief integration officer and Jonathan Woodring as ...

Not satisfied with simply changing personnel, Japanese drugmaker Astellas has announced a new management structure, effective ...

Pfizer & Astellas’ Padcev plus Keytruda shows long-term efficacy in first-line treatment of locally advanced or metastatic urothelial cancer: New York Wednesday, February 12, 20 ...

IZERVAY dosing approved beyond 12 months TOKYO, Feb. 12, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today ...